Actinium Pharmaceuticals (ATNM) Stock Rating Upgraded by Zacks Investment Research

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm presently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 4.17% from the stock’s current price.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

Several other equities analysts also recently commented on ATNM. B. Riley started coverage on shares of Actinium Pharmaceuticals in a report on Wednesday, December 6th. They issued a “buy” rating and a $2.75 target price on the stock. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, Roth Capital reissued a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $3.75.

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) traded up $0.02 on Tuesday, hitting $0.72. 760,600 shares of the company’s stock were exchanged, compared to its average volume of 633,000. The company has a market capitalization of $56.02, a price-to-earnings ratio of -1.53 and a beta of 41.30. Actinium Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $1.72.

ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals (ATNM) Stock Rating Upgraded by Zacks Investment Research” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/09/actinium-pharmaceuticals-atnm-stock-rating-upgraded-by-zacks-investment-research.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit